Evidence of a treatable endocrinopathy in infertile men.
OBJECTIVE
We establish whether a subset of infertile men have decreased serum testosterone-to-estradiol ratios and whether this condition can be corrected with an oral aromatase inhibitor.


METHODS
The serum testosterone-to-estradiol ratios of 63 men with severe male factor infertility or hypergonadotropic hypogonadism (mean follicle-stimulating hormone 21.2 +/- 1.8) were compared with those of an age matched, fertile, control reference group. Of the 63 men 43 were azoospermic with biopsy proved severe male infertility and 20 were oligospermic. The men with the lowest ratios (less than 20th percentile) were treated with 50 to 100 mg of the aromatase inhibitor testolactone orally twice daily. Testosterone-to-estradiol ratios and semen analyses were evaluated during testolactone therapy.


RESULTS
Men with severe male infertility had significantly lower testosterone (328 versus 543 ng/dl, p <0.01) and higher estradiol (58.4 versus 43.5 ng/l, p = 0.01) than fertile control reference subjects, resulting in a decreased testosterone-to-estradiol ratio (x10(-1) = 6.9 +/- 0.6 versus 14.5 +/- 1.2, respectively, p <0.01). Of the 45 men treated with testolactone a correction of these abnormalities was seen and ratios (x10(-1)) increased into the normal range (5.0 +/- 0.3 to 12.7 +/- 1.2, p <0.01). Semen analyses were considered evaluable only in men with sperm in the ejaculate before aromatase inhibitor treatment. Semen analyses before and during testolactone treatment revealed significant increases in sperm concentration (16.1 to 28.9 million sperm per ml, p = 0.03) and motility (27.1% to 45.3%, p <0.01) in 12 oligospermic men.


CONCLUSIONS
We identified an endocrinopathy in men with severe male factor infertility that is characterized by a decreased serum testosterone-to-estradiol ratio. This ratio can be corrected by aromatase inhibition, resulting in a significant improvement in semen parameters in oligospermic patients.
Pavlovich
C P
CP
James Buchanan Brady Urology Foundation and Cornell Institute for Reproductive Medicine, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York, USA.
King
P
P
Goldstein
M
M
Schlegel
P N
PN
D004700:Endocrine System Diseases / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007248:Infertility, Male / Q000097:blood / Q000209:etiology*; D008297:Male; D013738:Testolactone / Q000627:therapeutic use*; D013739:Testosterone / Q000097:blood
D013739:Testosterone; D013738:Testolactone